Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.04 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: letrozole, anastrozole, testolactone +3 | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 5 Parkinson's papers of 2,306 | 0.76 |
| pathways Reactome | 3 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 5581
Sealed predictions
- CYP19A1 in dopamine neurons, braak+0.24 (p 0.534) → -0.16 (p 0.689)receipt 5588
Swarm cases
receipt 5588: CYP19A1 in dopamine neurons, braak
- power
- full sample +0.03 (p 0.894, n 18), 95% CI -0.44 to +0.49. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.05 (p 0.847, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.23 (p 0.355, n 18). could be the mix.
- skeptic
- leave-one-out range -0.07 to +0.17, sign flips 5; without severely affected donors +0.03 (p 0.894, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CYP19A1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts